Updated EU requirements dictate that Thuringian wastewater treatment facilities face costly refurbishments - Stricter EU Regulations: Thuringian Waste Treatment Plants Facing Costly Renovations
In Thuringia, Germany, wastewater treatment plants are gearing up for significant changes, as the European Union (EU) has imposed stricter limits on micro-pollutants such as medication residues and cosmetics in the Urban Wastewater Directive.
The European Press Agency (EPA) has been reporting on the situation in Thuringia, with a focus on the Bayer Corporation, a pharmaceutical company based in the region. While Bayer is a key player in Thuringia's pharmaceutical industry, it is not the main source of micro-pollutants in the region's wastewater.
Most of the micro-pollutants in Thuringia's wastewater come from excretions and improper disposal of medication. In Weimar, for instance, wastewater from the Bayer site is pre-treated and then sent to the municipal wastewater treatment plant, which is approved by authorities. However, only a small part of the micro-pollutants in Thuringia's wastewater comes from Bayer's medicine production.
Bernd Hubner, the Thuringian state chairman of the Association for Water Management, Wastewater and Waste, expects these changes to result in increased fees due to the necessary investments. The investments will be financed through loans and refinanced through fees and charges over the depreciation period.
The new EU directive also requires that 70 percent of the necessary energy for larger wastewater treatment plants be covered by renewable energy. Moreover, around 30 smaller Thuringian wastewater treatment plants that discharge into sensitive waters, like drinking water catchment areas or bathing waters, will also require expansion.
One of the key changes is the introduction of a fourth treatment stage, which will remove trace substances, such as insulin preparations and other medications, from wastewater in a complex process. Current methods are not sufficient for this removal process, and the new stage is expected to address this issue.
However, the distribution of costs for these improvements is still a contentious issue. The EU directive states that 80% of the costs for the construction and operation of new treatment plants should be borne by pharmaceutical companies. Pharmaceutical companies, including Bayer, are currently challenging this cost distribution before the European Court of Justice.
If the European Court of Justice rules in favour of the EU directive, pharmaceutical companies operating in Thuringia may contribute to parts of the costs for the improved wastewater treatment plants' construction and operational expenses. This would potentially lead to a fairer distribution of wastewater treatment costs among industries, including pharma.
Wastewater samples from Thuringia's treatment plants, including the Weimar plant, are regularly checked by an independent, licensed measuring laboratory to ensure compliance with the new standards. As Thuringia works towards meeting the EU's stricter wastewater treatment requirements, it is clear that significant investments are needed to ensure the region's water remains clean and safe.
Read also:
- visionary women of WearCheck spearheading technological advancements and catalyzing transformations
- Recognition of Exceptional Patient Care: Top Staff Honored by Medical Center Board
- A continuous command instructing an entity to halts all actions, repeated numerous times.
- Oxidative Stress in Sperm Abnormalities: Impact of Reactive Oxygen Species (ROS) on Sperm Harm
